News
Latest news
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

CG Oncology

November 30 2023
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Arrivent Biopharma

October 30 2023
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC

Arrivent Biopharma

September 10 2023
ADARx Announces Oversubscribed $200 Million Series C Financing

ADARx Pharmaceuticals

August 09 2023
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline

CG Oncology

August 02 2023
ArriVent Closes $155 Million Oversubscribed Series B Financing

Arrivent Biopharma

March 27 2023

Get In Touch

Contact Us